Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 61
Filtrar
1.
New Phytol ; 242(5): 1981-1995, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38511237

RESUMO

Understanding the capacity of temperate trees to acclimate to limited soil water has become essential in the face of increasing drought risk due to climate change. We documented seasonal - or phenological - patterns in acclimation to water deficit stress in stems and leaves of tree species spanning the angiosperm phylogeny. Over 3 yr of field observations carried out in two US arboreta, we measured stem vulnerability to embolism (36 individuals of 7 Species) and turgor loss point (119 individuals of 27 species) over the growing season. We also conducted a growth chamber experiment on 20 individuals of one species to assess the mechanistic relationship between soil water restriction and acclimation. In three-quarters of species measured, plants became less vulnerable to embolism and/or loss of turgor over the growing season. We were able to stimulate this acclimatory effect by withholding water in the growth chamber experiment. Temperate angiosperms are capable of acclimation to soil water deficit stress, showing maximum vulnerability to soil water deficits following budbreak and becoming more resilient to damage over the course of the growing season or in response to simulated drought. The species-specific tempo and extent of this acclimatory potential constitutes preadaptive climate change resilience.


Assuntos
Aclimatação , Secas , Magnoliopsida , Filogenia , Estações do Ano , Estresse Fisiológico , Água , Magnoliopsida/fisiologia , Magnoliopsida/genética , Magnoliopsida/crescimento & desenvolvimento , Aclimatação/genética , Madeira/fisiologia , Especificidade da Espécie , Caules de Planta/fisiologia , Caules de Planta/crescimento & desenvolvimento , Folhas de Planta/fisiologia , Desidratação , Solo , Árvores/fisiologia
2.
Med Mycol ; 48(2): 394-7, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19657959

RESUMO

Rhino-cerebral zygomycosis (RCZ) is an acute rapidly progressive fungal infection usually occurring in patients with diabetes mellitus and ketoacidosis. Patients typically complain of pain located in the facial, nasal or orbital regions, followed by sudden blindness and cranial nerve palsy. Early diagnosis, correction of risk factors, prompt surgical removal and aggressive antifungal therapy are warranted as life-saving treatments. The following report describes a case of a lethal RCZ which occurred in an apparently healthy woman with latent non-decompensated diabetes mellitus and a fetal-type posterior (FTP) circle of Willis.


Assuntos
Encefalopatias/diagnóstico , Círculo Arterial do Cérebro/anormalidades , Complicações do Diabetes/microbiologia , Doenças Nasais/diagnóstico , Zigomicose/diagnóstico , Doença Aguda , Cegueira/etiologia , Encefalopatias/microbiologia , Encefalopatias/patologia , Evolução Fatal , Feminino , Humanos , Angiografia por Ressonância Magnética , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Doenças Nasais/microbiologia , Doenças Nasais/patologia , Fatores de Risco , Zigomicose/microbiologia , Zigomicose/patologia
3.
J Clin Oncol ; 9(4): 664-9, 1991 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-2066763

RESUMO

In this prospective randomized study, first-line treatment with the combination of cisplatin (P) and etoposide (E) was compared with the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in 140 patients. Complete remissions were obtained in 11% of 65 assessable patients on CMF and in 12% of 65 assessable patients on PE. Complete plus partial remission rates were 48% on CMF and 63% on PE (P = .08). Time to progression (median, 32 v 31 weeks), duration of response (48 v 39 weeks), and survival (75 v 76 weeks) were not different. Hematologic toxicity was significantly higher with PE, and gastrointestinal side effects were frequent with this treatment. This study demonstrated that the PE combination is effective as front-line chemotherapy. As far as response rate is concerned, a trend of superiority over CMF was observed, which was of borderline significance. Due to the lack of survival advantage and to toxicity, this combination is not recommended for routine clinical use. However, its high level of activity should be taken into account for further research.


Assuntos
Adenocarcinoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Adenocarcinoma/secundário , Adulto , Idoso , Neoplasias da Mama/patologia , Cisplatino/administração & dosagem , Ciclofosfamida/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Humanos , Metotrexato/administração & dosagem , Pessoa de Meia-Idade
4.
J Clin Oncol ; 10(6): 984-9, 1992 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-1588379

RESUMO

PURPOSE: A randomized study comparing low-dose aminoglutethimide (AG) with and without hydrocortisone (HC) was performed to investigate whether corticosteroid replacement contributes to the therapeutic effects of the drug administered as a front-line endocrine therapy in postmenopausal advanced breast cancer. PATIENTS AND METHODS: Postmenopausal patients who had not had prior endocrine therapy for advanced disease and with estrogen receptor (ER) or progesterone receptor (PgR) status positive or unknown were eligible. AG was administered at a dose of 250 mg twice a day orally (125 mg twice a day during the first month) with or without HC (20 mg twice a day orally). Seventy-nine and 74 patients were assessable for response on the AG plus HC arm and on the AG arm, respectively. The two treatment groups were well balanced and patients were largely untreated. Approximately 60% had not received any adjuvant treatment, and approximately 75% had not received any medical treatment after relapse. RESULTS: The overall responses (complete response [CR] plus partial response [PR]) were 44% and 41% for the AG plus HC and the AG arm, respectively, showing no significant difference. Time to progression (median, 8.1 and 6.3 months), duration of response (median, 15.8 and 13.7 months), and duration of survival (median, 34.2 and 36.3 months) were not significantly different between the two treatment arms. Side effects were infrequent and mild in both arms, with no significant differences. CONCLUSION: We conclude that half of the conventional daily dose of AG has optimal therapeutic activity as a front-line endocrine treatment of postmenopausal advanced breast cancer and that HC does not significantly contribute to the therapeutic effects.


Assuntos
Adenocarcinoma/tratamento farmacológico , Aminoglutetimida/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Hidrocortisona/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Aminoglutetimida/efeitos adversos , Quimioterapia Combinada , Feminino , Humanos , Hidrocortisona/efeitos adversos , Pessoa de Meia-Idade , Estudos Prospectivos
5.
Eur J Cancer ; 34(12): 1974-6, 1998 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10023325

RESUMO

The aim of this randomised trial was to compare the efficacy of bolus versus continuous infusion cisplatin combined with mitomycin C and vindesine (MVP) for chemotherapy-naive patients with stage IIIB-IV non-small cell lung cancer (NSCLC). 97 patients (49 given bolus cisplatin-arm A and 48 given continuous infusion cisplatin--arm B) were evaluable for response. In arm A, 2 patients achieved a complete response (CR), 21 achieved a partial response (PR), whilst in arm B, 14 patients achieved a PR (29%) (P = 0.07). Median survival was 8 months in both arms. Myelosuppression was the most frequent and severe toxicity, with a higher incidence of grade 3-4 leucopenia in arm A when compared with arm B (44% versus 25%). In conclusion, there is no advantage for a cisplatin 5 day infusion in the MVP regimen.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Idoso , Cisplatino/administração & dosagem , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Mitomicinas/administração & dosagem , Estudos Prospectivos , Vindesina/administração & dosagem
6.
Lung Cancer ; 12 Suppl 1: S125-32, 1995 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7551920

RESUMO

To evaluate the efficacy of a three-drug regimen vs. a two-drug CDDP based combination in the treatment of NSCLC, we conducted a three-arm randomized parallel trial comparing (a) CDDP (120 mg/m2 day 1) + etoposide (100 mg/m2 days 1-3) every 3 weeks (PE--arm A); (b) CDDP (120 mg/m2 every 4 weeks) + mitomycin (8 mg/m2 days 1, 29, 71) + vindesine (3 mg/m2 days 1, 8, 15, 22 every 2 weeks) (MVP--arm B); and (c) CDDP (120 mg/m2 day 1) + mitomycin (6 mg/m2 day 1) + ifosfamide (3 g/m2 day 2) every 3 weeks (MIC--arm C). From May 1989 to April 1992, 393 consecutive previously untreated patients with NSCLC Stage IIIB and IV entered the trial; 373 were evaluable for survival and 360 for response. The response rate was significantly better for both the three-drug regimens compared with PE (Table 3). Logistic regression model showed a significantly better response in patients with a good P.S. and in Stage IIIB. Main toxicity consisted of myelosuppression: neutropenia Grade III-IV was recorded in 14% (arm A), 15% (arm B) and 21% (arm C). Thrombocytopenia Grade III-IV was worst in arm C: 10% vs. 5% (arm A) and 3% (arm B). Nephrotoxicity Grade III-IV was more common in arm C: 3.5%. Toxic deaths were 11 (3%: three in arm A, five in arm B, three in arm C). From our data, the three-drug containing regimens, MVP and MIC, appear more active than the two-drug combination PE in treatment of advanced NSCLC.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Feminino , Humanos , Ifosfamida/administração & dosagem , Ifosfamida/efeitos adversos , Neoplasias Pulmonares/mortalidade , Masculino , Mitomicina/administração & dosagem , Mitomicina/efeitos adversos , Taxa de Sobrevida , Resultado do Tratamento , Vindesina/administração & dosagem , Vindesina/efeitos adversos
7.
Br J Ophthalmol ; 87(8): 1038-42, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12881351

RESUMO

BACKGROUND/AIMS: Many cytokines are involved in the pathogenesis of retinal proliferative diseases, but none has been shown to be related to a specific disorder. The aim of this study was to provide a selective marker of diabetes induced proliferative retinopathies. METHODS: 10 vitreous samples from 10 subjects affected by quiescent proliferative diabetic retinopathy (PDR), 20 vitreous samples from 20 subjects affected by active PDR, and 15 samples from 15 patients with proliferative vitreoretinopathy (PVR) were studied. Samples from 18 patients with a macular hole (n = 8) or pucker (n = 10) served as controls. Vitreous samples were obtained via pars plana vitrectomy. The polyamines spermidine, putrescine, and spermine, vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), and transforming growth factor 1beta (TGF-1beta) were measured by high performance liquid chromatography (HPLC) and enzyme linked immunosorbent assay (ELISA), and the correlation coefficients between the vitreous polyamine content and VEGF, IL-8, and TGF-1beta levels were determined. RESULTS: Spermidine and putrescine were expressed in normal vitreous, but spermine was not detectable. In all the test groups spermidine was 3-4 times higher than in control vitreous and putrescine was similarly lower. The spermine content was up to 15 times higher only in vitreous from patients affected by PDR. Correlation coefficients showed that the spermidine and putrescine level variations correlated with the VEGF and IL-8 content in the active PDR and PVR groups, but not in those with quiescent PDR patients, while spermine was correlated to these cytokines in PDR, but not in PVR groups. CONCLUSIONS: These data suggest a significant role for spermidine and putrescine as markers of proliferative diseases of the retina. The increase in spermine, restricted to diabetic states, may indicate that this polyamine is a unique and specific index of PDR.


Assuntos
Retinopatia Diabética/metabolismo , Putrescina/análise , Corpo Vítreo/química , Adulto , Idoso , Biomarcadores/análise , Cromatografia Líquida de Alta Pressão/métodos , Fatores de Crescimento Endotelial/análise , Humanos , Peptídeos e Proteínas de Sinalização Intercelular/análise , Interleucina-8/análise , Linfocinas/análise , Pessoa de Meia-Idade , Espermidina/análise , Espermina/análise , Fator de Crescimento Transformador beta/análise , Fator de Crescimento Transformador beta1 , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular
8.
Am J Clin Oncol ; 22(6): 559-67, 1999 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10597739

RESUMO

In a retrospective analysis of a series of clinical trials by Levin and Hryniuk in 1987, the average relative dose intensity of first-line chemotherapy for advanced ovarian cancer correlated significantly with clinical response and survival, and cisplatin was the only drug for which the outcome correlated with the individual drug relative dose intensity. There was a need to test whether and to what extent this evidence would be confirmed in a prospective evaluation. In this study 101 patients with advanced ovarian carcinoma were randomized to receive the same total dose of cisplatin but at the conventional 3-weekly schedule (CTWS) (100 mg/m2 every 3 weeks for six cycles) (51 patients) or at an experimental accelerated weekly schedule (AWS) (100 mg/m2 every week for two triplets of three cycles separated by a 5-week interval) (50 patients). To benefit from a multidrug regimen at the same extent, patients in both arms sequentially received four cycles of doxorubicin and cyclophosphamide. The median follow-up period of this study is 9.7 years. In 42 and 40 patients of the two arms having evaluable response, the clinical complete response rates to cisplatin were 14% and 22% and the complete plus partial response rates were 48% and 55% in the CTWS and in the AWS arm, respectively. These differences were not statistically significant. However, the survival curves were similar during the first 2 years but clearly diverged thereafter in favor of the AWS arm (p = 0.07). At 5 years, 12% and 30% of the patients were still alive in the CTWS and in the AWS arm, respectively. Hematologic toxicity was not relevant in either arm of the study. Nonhematologic toxicity, especially ototoxicity, was substantial and significantly higher in the AWS arm. Although statistically nonsignificant, this AWS regimen of cisplatin is associated with long-term better survival compared to the CTWS regimen in advanced ovarian carcinoma. This accelerated approach administering cisplatin should be further investigated, especially in patients with low residual disease after primary surgery.


Assuntos
Antineoplásicos/administração & dosagem , Carcinoma/tratamento farmacológico , Cisplatino/administração & dosagem , Neoplasias Ovarianas/tratamento farmacológico , Adulto , Idoso , Antibióticos Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Antineoplásicos Alquilantes/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma/cirurgia , Quimioterapia Adjuvante , Cisplatino/efeitos adversos , Ciclofosfamida/administração & dosagem , Relação Dose-Resposta a Droga , Doxorrubicina/administração & dosagem , Esquema de Medicação , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasia Residual , Neoplasias Ovarianas/cirurgia , Estudos Prospectivos , Indução de Remissão , Taxa de Sobrevida , Resultado do Tratamento
9.
Tumori ; 71(5): 483-9, 1985 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-2865833

RESUMO

From July 1980 to June 1983, 61 postmenopausal women with progressive metastatic breast cancer were treated with aminoglutethimide, 250 mg 4 times daily, plus cortisone acetate, 25 mg twice daily. Of 51 evaluable patients, an objective remission was observed in 22 (43%) (partial remission in 19, complete in 3), stable disease in 14 (27%), and progressive disease in 15 (30%). The median duration of response was 60 weeks (range 12+; 94+). The response rate was higher when the dominant disease site was soft tissue (50%) or bone (56%) rather than viscera (29%). Side effects were common but usually slight and transient. Somnolence (69%), dizziness (41%), nausea (35%) and skin rash (27%) were the most frequent. Serum levels of gamma-GT, alkaline phosphatase and total cholesterol rose during aminoglutethimide treatment, whereas levels of uric acid and indirect bilirubin decreased. Aminoglutethimide plus cortisone acetate appears to be an active and relatively safe treatment in advanced breast cancer and may be recommended as second-line endocrine treatment.


Assuntos
Aminoglutetimida/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Adulto , Idoso , Fosfatase Alcalina/sangue , Aminoglutetimida/efeitos adversos , Feminino , Humanos , Menopausa , Pessoa de Meia-Idade , Receptores de Estrogênio/análise , Receptores de Progesterona/análise , Tamoxifeno/uso terapêutico , gama-Glutamiltransferase/sangue
10.
Tumori ; 81(4): 241-4, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8540119

RESUMO

AIMS AND BACKGROUND: The study was designed to define the activity of the combination of cisplatin and etoposide as third-line chemotherapy for advanced breast cancer and to investigate the role of the dosage of cisplatin on the effectiveness of the combination. METHODS: Ninety-five eligible patients with advanced breast cancer who had failed or relapsed on two previous lines of chemotherapy were randomized to receive cisplatin at a high dose (100 mg/m2 i.v. day 1, arm A) or a low dose (60 mg/m2 day 1, arm B), combined with etoposide (100 mg/m2 i.v. days 4, 6 and 8). Cycles were repeated every 3 weeks. RESULTS: Of the 78 patients evaluable for response (39 in arm A and 39 in arm B), 9 (12%) showed complete or partial response, 5 (13%) in the high-dose arm and 4 (10%) in the low-dose arm. One complete response was seen in the high-dose arm and none in the low-dose arm. The only 2 patients with brain involvement showed an objective response (one CR in arm A and one PR in arm B). Median time to progression was 14 weeks in arm A and 10 weeks in arm B, median duration of remission 28 and 34 weeks, and survival 36 and 35 weeks, respectively. The differences were not significant. As expected, the patients in the high-dose arm experienced more severe toxicity. One toxic death was observed in each arm due to sepsis in agranulocytosis. The difference was statistically significant regarding nausea and vomiting. Neurotoxicity and ototoxicity were not relevant problems in this patient setting. CONCLUSIONS: Considering the very poor prognostic factors presented by these patients, the combination showed a certain activity, and further evaluation in earlier stages of disease is warranted. A particular responsiveness on brain metastases is suggested. The dose of cisplatin was not proven to be of significant importance.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Cisplatino/administração & dosagem , Adulto , Idoso , Antineoplásicos Fitogênicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias da Mama/patologia , Esquema de Medicação , Etoposídeo/administração & dosagem , Feminino , Humanos , Pessoa de Meia-Idade , Análise de Sobrevida , Resultado do Tratamento
11.
Tumori ; 75(6): 576-9, 1989 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-2559525

RESUMO

From April 1982 to December 1987, 71 patients with small cell lung cancer entered a randomized clinical trial, and underwent bone marrow biopsy (BMB) as part of staging procedures. We identified 8 patients (11%) with bone marrow metastases, 6 with extensive disease independently of BMB, and 2 with extensive disease on the basis of the BMB only. BMB determined a change in the stage in only 3% (2/71) of the cases. No differences were found in the hematological parameters of the patients with or without bone marrow metastases. The median survival of the patients with bone marrow involvement was the same (41 weeks) as those with extensive disease but without bone marrow involvement. We conclude that unilateral BMB without aspiration detects a substantial proportion of bone marrow metastases in patients with extensive disease. This fact does not worsen the prognosis. A small proportion of patients with apparently limited disease has bone marrow involvement. The technique therefore contributes, to a small extent, to the definition of the clinical stage of the disease. However, bone marrow involvement is an important data of natural history, and therefore new methods to better assess this peculiar site of the disease are needed.


Assuntos
Medula Óssea/patologia , Carcinoma de Células Pequenas/patologia , Neoplasias Pulmonares/patologia , Adulto , Idoso , Carcinoma de Células Pequenas/mortalidade , Carcinoma de Células Pequenas/secundário , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Ensaios Clínicos Controlados Aleatórios como Assunto
12.
New Microbiol ; 27(3): 281-5, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15460531

RESUMO

A 33-year-old woman underwent a liver transplantation and splenectomy in 1985 and had followed immunosuppressive therapy until 1995. Afterwards a non-Hodgkin lymphoma was diagnosed and chemotherapy was started. In January 2000, because of suspect transplantation rejection she was treated with steroid and immunosuppressive therapy. Fever occurred after two months and Cytomegalovirus (CMV) infection was diagnosed. Ganciclovir was started with clinical remission. In November 2000 fever recurred without clinical symptoms. Lymphoma recurrence was excluded and CMV was detected by PCR in several biological fluids. Blood cultures were positive for a bacterium that was identified as Campylobacter fetus. The patient was successfully treated with intravenous ciprofloxacin. For persistent CMV viremia therapy with gancyclovir was stopped and foscarnet was used (60mg/Kg/tid i.v. for two weeks). Bacteremia due to C. fetus is rare, occurring mainly in immunocompromised patients. In our patient the immunosuppressive therapy, chemotherapy for lymphoma and CMV infection had made the patient susceptible to bacteremia with this infrequently found bacterium. The clinical microbiologist should be aware of this infection in immunocompromised hosts.


Assuntos
Bacteriemia/microbiologia , Infecções por Campylobacter/microbiologia , Campylobacter fetus/isolamento & purificação , Hospedeiro Imunocomprometido , Adulto , Bacteriemia/tratamento farmacológico , Infecções por Campylobacter/tratamento farmacológico , Ciprofloxacina/uso terapêutico , Citomegalovirus/isolamento & purificação , Feminino , Foscarnet/uso terapêutico , Ganciclovir/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Transplante de Fígado , Esplenectomia , Esteroides/uso terapêutico
17.
Ann Ostet Ginecol ; 94(2): 131-6, 1973.
Artigo em Inglês | MEDLINE | ID: mdl-12333785

RESUMO

PIP: Pemphigus during pregnancy is discussed as an indication for therapeutic abortion. The case of a 46-year-old woman, suffering from pemphigus for 2 years, who had a therapeutic abortion in the 17-18th week of pregnancy, is described. Pemphigus had been aggravated by pregnancy, and the patient was treated with corticosteroids, since maternal prognosis depends upon early and massive cortisone treatment. Abortion was indicated because of the fetal deformities and pregnancy complications ascribed to corticosteroids by many authors. Incomplete abortion was induced by saline injection followed by oxytocin slow drip infusion, and instrumental emptying of the uterine cavity. The patient died 1 month later of bronchopulmonary complications of pemphigus. Pemphigus in pregnancy is compared with cervical cancer in the discussion of indications for therapeutic abortion.^ieng


Assuntos
Aborto Terapêutico , Complicações na Gravidez , Pele , Aborto Induzido , Corticosteroides , Biologia , Anormalidades Congênitas , Doença , Serviços de Planejamento Familiar , Fisiologia , Pesquisa , Neoplasias do Colo do Útero
18.
Eur J Clin Microbiol Infect Dis ; 15(2): 116-20, 1996 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8801082

RESUMO

To assess the prevalence of hepatitis C virus (HCV) infection in pregnant women and the rate of vertical transmission in infected mothers belonging to a low-risk group, 1,388 women were tested for HCV antibody at delivery. Twenty-five anti-HCV-positive women with no apparent source of HCV exposure were recruited. A reverse transcriptase-polymerase chain reaction (RT-PCR) and a new quantitative branched DNA-based signal amplification assay (bDNA) were used to detect HCV RNA. The rate of anti-HCV positivity in pregnant women was 2.5% (36 of 1,388). Of the 25 cohort mothers, 18 (72%) were positive for HCV RNA by RT-PCR, 13 of whom were also positive by the bDNA assay (sensitivity 72.2%). Of the 25 infants of low-risk mothers tested at birth, 22 were anti-HCV positive, two were weakly reactive, one was negative, and none was viremic. Neither active humoral immunoresponse nor HCV RNA was detected in any of the infants over a period of 12 months. These data suggest a relatively high prevalence of anti-HCV in unselected pregnant women and a poor efficiency of vertical transmission of HCV in a low-risk population, irrespective of the viral burden of the mother-to-be.


Assuntos
Hepacivirus/isolamento & purificação , Hepatite C/transmissão , Transmissão Vertical de Doenças Infecciosas , Complicações Infecciosas na Gravidez/imunologia , Adulto , Sequência de Bases , Estudos de Coortes , Primers do DNA , Feminino , Hepatite C/congênito , Hepatite C/epidemiologia , Hepatite C/imunologia , Anticorpos Anti-Hepatite C/análise , Humanos , Imunidade Materno-Adquirida/imunologia , Recém-Nascido , Transmissão Vertical de Doenças Infecciosas/estatística & dados numéricos , Dados de Sequência Molecular , Sondas de Oligonucleotídeos , Reação em Cadeia da Polimerase , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Prevalência , Estudos Prospectivos , RNA Viral/análise , Testes Sorológicos
19.
Ann Oncol ; 2(9): 687-8, 1991 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1742225

RESUMO

The cisplatin (P) and etoposide (E) combination has been found to be active in several types of solid tumors. It has never been previously tested in advanced colorectal cancer. Thirty-three patients with advanced colorectal cancer were treated with this combination. Five patients responded (1 complete and 4 partial responses) with an overall response rate of 15% (95% confidence limits, 3%-27%). Responses were seen in both untreated (3/16) and pretreated (2/17) patients. The median duration of response was 28 weeks (range: 23; 80), the median time to progression was 16 weeks (range 2; 80) and the median survival time for all entered patients was 38 weeks (range: 2; 187+). These results suggest that the PE combination has a low but definite activity in advanced colorectal carcinoma, particularly in previously untreated patients.


Assuntos
Adenocarcinoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Colorretais/tratamento farmacológico , Adulto , Idoso , Cisplatino/administração & dosagem , Avaliação de Medicamentos , Etoposídeo/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Indução de Remissão
20.
Immunol Cell Biol ; 79(5): 482-9, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11564156

RESUMO

Prostaglandin E-induced signal transduction pathways in human T cells from healthy and uveal melanoma-bearing subjects were studied. Transfection experiments showed that PGE2 was able to phosphorylate and activate the fusion trans-activator of the cAMP responsive element-binding protein (CREB). Phosphorylation was at least partially mediated by protein kinase A, as evidenced by the effects of specific kinase inhibitors. Western blotting experiments, which were performed to identify the CREB/ATF2 family members involved in the response to PGE2, revealed a modulation of proteins CREB1, CREB2 and ATF2 and phosphorylation of the 43 kDa form of CREB. Experiments of immunoprecipitation with CREB-binding protein (CBP) demonstrated that, after PGE2 treatment, all of the CREB/ATF isoforms studied, as well as the phosphorylated form of CREB (p-CREB), interacted with CBP. In basal conditions, T cells from patients with conjunctiva basal cell carcinoma showed the presence of p-CREB, which coimmunoprecipitated with CBP. CREB phosphorylation did not modify after PGE2 treatment whereas the p-CREB fraction bound to CBP increased in a delayed manner compared to normal subjects.


Assuntos
Carcinoma Basocelular/imunologia , Neoplasias da Túnica Conjuntiva/imunologia , Dinoprostona/metabolismo , Transdução de Sinais , Linfócitos T/metabolismo , Fator 2 Ativador da Transcrição , Adulto , Carcinoma Basocelular/metabolismo , Neoplasias da Túnica Conjuntiva/metabolismo , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/genética , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/metabolismo , Genes Reporter , Humanos , Immunoblotting , Células Jurkat , Fosforilação , Testes de Precipitina , Proteínas Recombinantes de Fusão/metabolismo , Proteína do Retinoblastoma/metabolismo , Linfócitos T/imunologia , Fatores de Transcrição/metabolismo , Ativação Transcricional
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa